bioAffinity Technologies, Inc.
$0.09 -$0.01 (-12.50%) 1DKey Metrics
The Story So Far
LAST 6 MONTHS PRIMARY SOURCES ONLY-
Jul 27
A material event was filed (Form 8-K).
8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)
RECEIPT: SEC FORM 8-K, TIMESTAMPED -
Jul 22
A material event was filed (Form 8-K).
8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)
RECEIPT: SEC FORM 8-K, TIMESTAMPED -
Jul 16
Money rotated out of high-beta cohorts market-wide.
High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.
RECEIPT: ROTATION GAUGE, LIVE -
Jul 15
From its Mar 23 high, the share price fell 85%.
Peak close $0.56 on Mar 23; trough close $0.08 on Jul 15. The drawdown is the fact — the chapters around it are the context.
RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -85% -
Mar 23
The stock moved +63.2% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Mar 23 -
Mar 17
The stock moved +103.3% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Mar 17
The story updates itself as events post · The wolf reports; you decide
Snapshot
About bioAffinity Technologies, Inc.
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI).
Wolf Grade COMING SOON
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.